TangP., TsaoM., MooreM.: A review of erlotinib and its clinical use.Expert Opin Pharmacother2006; 7: 177–193.
2.
GatzemeierU., PluzanskaA., SzczesnaA.: Results of a phase III trial of erlotinib combined with cisplatin and gemcitabine chemotherapy in advanced NSCLC.J Clin Oncol2004; 22 (14S): abstr 7010.
3.
HerbstR.S., PragerD., HermannR.: TRIBUTE: a phase III trial of erlotinib-hydrochloride combined with carboplatin and paclitaxel chemotherapy in advanced NSCLC.J Clin Oncol2005; 23: 5892–5899.
4.
Perez-SolerR., ChachouaA., HammondL.A.: Determinants of tumor response and survival with erlotinib in patients with NSCLC.J Clin Oncol2004; 22: 3238–3247.
TsaoM.S., SakuradaA., CutzJ.C.: Erlotinib in lung cancer: molecular and clinical predictors of outcome.N Engl J Med2005; 353: 133–144.
7.
ShepherdF.A., DanceyJ., RamlauR.: A prospective randomized trial of docetaxel versus best supportive care in patients with NSCLC previously treated with platinum-based chemotherapy.J Clin Oncol2000; 18: 2095–2103.
8.
AkerleyW., MajerM., ArbogastK.: Erlotinib as first-line treatment for untreated stage IV NSCLC with good prognosis.Proc ASCO2006: abstr 7178.
9.
ClarkG.M., CameronT., Das-GuptaA.: Clinical benefit of erlotinib in male smokers with squamous-cell carcinoma.Proc ASCO2006: abstr 7166.
10.
GurpideB., MassutiC., PallaresP.: Erlotinib in patients with advanced squamous cell carcinoma of the lung.Proc ASCO2006: abstr 7174.
11.
JackmanD.M., YeapB., LuccaJ.: Phase II trial of erlotinib in elderly patients with previously untreated advanced non-small cell lung cancer (NSCLC): quality of life and symptom analysis.Proc ASCO2006: abstr 7168.
12.
Paz-AresL., SanchezJ.M., Garcia-VelascoA.: A prospective phase II trial of erlotinib in advanced NSCLC patients with mutations in the TK domain of the EGFR.Proc ASCO2006: abstr 7020.
13.
GiacconeG.: Targeting HER1/EGFR in cancer therapy: experience with erlotinib.Future Oncol2005; 1: 449–460.
14.
CappuzzoF., HirschF.R., RossiE.: EGFR gene and protein and gefitinib sensitivity in NSCLC.J Natl Cane Inst2005; 97: 643–655.
15.
WeiQ., ChengL., AmosC.I.: Repair of tobacco-carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study.J Natl Cancer Inst2000; 92: 1764–1772.
16.
RosellR., CoboM., IslaR.: ERCC1 mRNA-based randomised phase III trial of docetaxel doublets with cisplatin or gemcitabine in stage IV NSCLC patients.Proc ASCO2005: abstr 7002.
